Patients starting pembrolizumab are often surprised to learn that corticosteroids - drugs that suppress the immune system - are one of the main tools for managing side effects of an immune-activating treatment. Understanding the logic behind this helps make sense of why steroids are an important part of the pembrolizumab treatment programme.
Why corticosteroids are used
Pembrolizumab works by releasing brakes on immune activity. In some patients, this leads to excessive immune activation directed against healthy tissue - immune-related adverse events (irAEs). Corticosteroids like prednisolone or methylprednisolone suppress the overactive immune response that is causing the tissue damage. They are used not to counteract pembrolizumab's effect on the tumour, but to control the collateral damage of immune over-activation in normal organs - the lung, bowel, liver, skin, and elsewhere.
Do steroids reduce the effectiveness of pembrolizumab?
This is the question patients ask most often - and the available evidence is reassuring. When corticosteroids are used at standard doses for the management of irAEs, they do not appear to significantly reduce pembrolizumab's anti-tumour efficacy. The tumour response achieved before the irAE developed is generally maintained. What matters is that the irAE is identified and treated promptly - untreated immune-related organ damage can be more harmful than the steroid treatment needed to manage it.
Where there may be more concern is with high-dose or prolonged steroid use that begins before or simultaneously with pembrolizumab (for example, patients on steroids for another medical condition). This is assessed on a case-by-case basis.
The typical steroid taper
Steroids for irAE management are not given indefinitely. Once symptoms resolve or improve, the dose is reduced gradually over several weeks (a taper). Stopping steroids too quickly can trigger recurrence of the irAE; stopping them appropriately allows normal immune function to resume. The taper schedule is guided by the severity and organ involved.
Resuming pembrolizumab after steroid treatment
After a Grade 2 irAE that resolves with steroid treatment, pembrolizumab can usually be resumed once the steroid dose is tapered to a low level and symptoms have settled. Grade 3 irAEs require a longer period of resolution and full steroid taper before the restart decision is made. Grade 4 irAEs, and some specific Grade 3 types (such as pneumonitis), typically lead to permanent discontinuation.
Want to understand how side effects are managed at home?
Side effect protocols and escalation pathways are covered on the Welcome Call. Start with the eligibility check.
Check your eligibility